

Supplementary Table S4: Antitumor Activity of MRTX0902 and Osimertinib in Human *EGFR* Mutant Tumor Cell line-derived Xenograft Models

Model	Tumor Type	MRTX0902 Treatment	Osimertinib Treatment	% Growth Inhibition ¹ / Regression ² (Day)	Response
PC9	NSCLC	50 mg/kg BID	n/a	8% (24) 13% (41)	TGI
		n/a	5 mg/kg QD	-28% (24) ³ 98% (80) ³	Regression; TGI
		50 mg/kg BID	5 mg/kg QD	-67% (24) ^{3,4} -35% (80) ^{3,4}	Regression
NCI-H1975	NSCLC	50 mg/kg BID	n/a	11% (27) 0% (31)	TGI
		n/a	5 mg/kg QD	91% (27) ³ 72% (77) ³	TGI
		50 mg/kg BID	5 mg/kg QD	-75% (27) ^{3,4} -43% (77) ^{3,4}	Regression

Abbreviations: BID = twice daily dosing; QD = once daily; NA = not applicable; NSCLC = non-small cell lung cancer; TGI = tumor growth inhibition

MRTX0902 was administered daily via oral gavage at 50 mg/kg BID (to mice bearing established tumor cell-derived xenografts (n = 5) with average starting volume of ~100 mm³. MRTX0902 was formulated in a suspension of 0.5% methylcellulose (4000 cps) + 0.2% Tween 80 in water.

Osimertinib was administered QD via oral gavage at 5 mg/kg QD to mice bearing established tumor cell-derived xenografts (n = 5) with average starting volumes of ~100 mm³. Osimertinib was formulated as a solution in 5%DMSO:45%PEG400:50%H₂O.

¹ Tumor growth inhibition (TGI) was calculated using the following equation: $100\% \times ((\text{Final vehicle tumor volume}) - (\text{Final treated tumor volume})) / ((\text{Final vehicle tumor volume}) - (\text{Initial Drug Treated Tumor Volume}))$. **Note:** TGI values are positive.

² Tumor regression was calculated when the average tumor volume of final treated tumors was less than initial treated tumor volume using the following equation: $(-100\%) \times (1 - ((\text{Final treated tumor volume}) / (\text{Initial treated tumor volume})))$.

³ indicates drug treated-tumor volumes are significantly different compared to vehicle-treated cohorts on the study day at which % TGI or Regression was calculated by the two-tailed Student's *t* test (*p*-value <0.05).

⁴ indicates drug treated-tumor volumes are significantly different compared to the equivalent concentration of osimertinib (monotherapy)-treated cohorts on the study day at which % TGI or Regression was calculated by the two-tailed Student's *t* test (*p*-value <0.05).